

1 **Self-reported and physiological reactions to the third BNT162b2 mRNA**

2 **COVID-19 (booster) vaccine dose**

3 **Running title: Reactions to the third Pfizer COVID-19 (booster) vaccine dose**

4 Merav Mofaz, MSc¹, Matan Yechezkel, MSc¹, Grace Guan, MSc², Margaret L. Brandeau, PhD², Tal Patalon, MD³,
5 Sivan Gazit, MD³, Dan Yamin, PhD^{1,4,+}, and Erez Shmueli, PhD^{1,5,+,*}

6 ¹Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel.

7 ²Department of Management Science and Engineering, Stanford University, Stanford CA, USA.

8 ³Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.

9 ⁴Center for Combatting Pandemics, Tel Aviv University, Tel Aviv, Israel.

10 ⁵MIT Media Lab, Cambridge MA, USA.

11 ⁺Equal contribution

12 *Corresponding author. Email: shmueli@tau.ac.il

13 **Keywords:** COVID-19 vaccine, third COVID-19 dose, booster vaccine, BNT162b2, adverse effects, wearables

14 **Abstract**

15 **Background:** The rapid rise in hospitalizations associated with the Delta-driven COVID-19
16 resurgence, and the imminent risk of hospital overcrowding, led the Israeli government to
17 initialize a national third (booster) COVID-19 vaccination campaign in early August 2021,
18 offering the BNT162b2 mRNA vaccine to individuals who received their second dose over five
19 months ago. However, the safety of the third (booster) dose has not been fully established yet.

20 **Objective:** Evaluate the short-term, self-reported and physiological reactions to the third
21 BNT162b2 mRNA COVID-19 (booster) vaccine dose.

22 **Design:** A prospective observational study, in which participants are equipped with a smartwatch
23 and fill in a daily questionnaire via a dedicated mobile application for a period of 21 days,
24 starting seven days before the vaccination.

25 **Setting:** An Israel-wide third (booster) vaccination campaign.

26 **Participants:** A group of 1503 (18+ years of age) recipients of at least one dose of the
27 BNT162b2 vaccine between December 20, 2020, and September 6, 2021, out of a larger cohort
28 of 2,848 prospective study participants. 1,231 of the participants were recipients of the third
29 vaccine dose.

30 **Measurements:** Daily self-reported questionnaires regarding local and systemic reactions, mood
31 level, stress level, sport duration, and sleep quality. Heart rate and heart rate variability were
32 continuously measured by Garmin Vivosmart 4 smartwatches.

33 **Results:** Local and systemic reactions reported following the third (booster) dose administration
34 are similar to those reported following the second dose and considerably greater than those
35 reported following the first dose. Our analyses of self-reported well-being indicators as well as
36 the objective heart rate and heart rate variability measures recorded by the smartwatches further

37 support this finding. These measures returned to their baseline levels within three days from
38 inoculation with the third dose. These trends were consistent regardless of age, gender or the
39 existence of an underlying medical condition.

40 **Limitations:** Participants may not adequately represent the vaccinated population in Israel and
41 elsewhere.

42 **Conclusion:** Our work further supports the safety of a third COVID-19 BNT162b2 mRNA
43 (booster) vaccine dose from both a subjective and an objective perspective.

44 **Primary funding source:** European Research Council (ERC) project #949850.

45

46 **Introduction:**

47 The SARS-CoV-2 Delta variant (also termed variant B.1.617.2) was discovered in October 2020,
48 in India, and was designated as a variant of concern by the World Health Organization (WHO) in
49 May 2021 (1–3). Since its discovery, it has spread worldwide and has rapidly become the most
50 dominant variant in many countries (4–7). Although the BNT162b2 COVID-19 vaccine is highly
51 effective against the Alpha variant (8), recent studies show that the effectiveness of the Pfizer-
52 BioNTech vaccines is notably lower against the Delta variant – 88% compared to 93.7% against
53 the Alpha variant (9–12). Moreover, recent evidence shows that fully vaccinated individuals
54 infected with the virus can easily transmit it further, as their peak viral burden is similar to that
55 observed in unvaccinated individuals (7,10). In Israel, the Delta variant has accelerated COVID-
56 19 infection and hospitalization, with numbers doubling every ten days between July 1, 2021 and
57 August 9, 2021 (7,13), despite the high coverage of the BNT162b2 vaccine in Israel during this
58 period—greater than 75% coverage with two Pfizer doses in the eligible population (individuals
59 ≥ 12 years of age) (13).

60

61 The rapid rise in hospitalizations associated with the Delta-driven COVID-19 resurgence, and
62 the imminent risk of hospital overcrowding, led the Israeli government to initialize on July 30,
63 2021, an unparalleled, pro-active, national third (booster) vaccine shot campaign, offering the
64 BNT162b2 mRNA COVID-19 vaccine to individuals over the age of 60. On August 13, 2021,
65 the booster campaign was expanded to include those over 50 years of age, reaching 63% third-
66 dose coverage among the eligible population within only 26 days (7,14–16). Two weeks later, on
67 August 29, 2021, the campaign was expanded to the general population, demanding only that
68 five months have passed since receipt of the second dose, reaching 40% third-dose coverage
69 among the eligible population under the age of 50, within 16 days (13,17).

70

71 Currently, limited information is available on the safety of a BNT162b2 third dose (18,19), with
72 such a booster vaccine yet to be authorized by the US Food and Drug Administration (FDA) to
73 the general population (20). While recent evidence shows that a third BNT162b2 dose in
74 immunocompromised individuals has a favorable safety profile (19,21), a formal clinical trial for
75 assessing the safety of a third (booster) dose in the general population has not yet been fully
76 established.

77

78 Here, we evaluate the short-term effects of a third BNT162b2 mRNA COVID-19 vaccine dose
79 on self-reported and physiological indicators. We followed a cohort of 2,848 participants; of
80 these, 1,503 participants received at least one dose of the BNT162b2 vaccine after joining the
81 study. Each participant received a dedicated mobile application and a Garmin Vivosmart 4

82 smartwatch. The mobile application collected daily self-reported questionnaires on local and
83 systemic reactions as well as various well-being indicators. The smartwatch continuously
84 monitored several physiological measures, including heart rate and heart rate variability (HRV).
85 Our analysis of the comprehensive data on each participant examines the safety of a third
86 (booster) vaccine dose from both a subjective perspective (patient questionnaire) and an
87 objective perspective (smartwatch data).

88

89 **Materials and Methods**

90 **Study design and participants**

91 Our study includes a prospective cohort of 2,848 participants (18+ years of age) who were
92 recruited between November 1, 2020 and September 6, 2021. The 1,503 participants who
93 reported receipt of at least one of the three BNT162b2 mRNA COVID-19 vaccine shots after
94 joining the study served as the base cohort for our analysis. Specifically, of these 1,503
95 participants, during the study, 223 received their first dose, 351 their second dose, and 1,231
96 their third dose.

97

98 We employed a professional survey company to recruit participants and ensure they follow
99 through with the study requirements. Participant recruitment was performed via advertisements
100 on social media and word-of-mouth. Each participant provided informed consent by signing a
101 form after receiving a comprehensive explanation on the study. Then, participants completed a
102 one-time enrollment questionnaire, were equipped with Garmin Vivosmart 4 smartwatches, and
103 installed two applications on their mobile phones: (1) the PerMed application (22) that collected
104 daily self-reported questionnaires, and (2) an application that passively recorded the smartwatch

105 data. Participants were asked to wear their smartwatches as much as possible. The survey
106 company ensured that participants' questionnaires were completed daily, that their smartwatches
107 were charged and properly worn, and that any technical problems with the mobile applications or
108 smartwatch were resolved.

109

110 **PerMed mobile application**

111 Participants used the PerMed mobile application (22) to fill out daily questionnaires. The
112 questionnaire allowed participants to report various well-being indicators, including mood level
113 (on a scale of 1 [awful] to 5 [excellent]), stress level (on a scale of 1 [very low] to 5 [very high]),
114 sport duration (in minutes), and sleep quality (on a scale of 1 [awful] to 5 [excellent]). The
115 questionnaire also collected data on clinical symptoms consistent with the local and systemic
116 reactions observed in the BNT162b2 mRNA Covid-19 clinical trial (23), with an option to add
117 other symptoms as free text. (For more details see Appendix A in the Supplemental Material)

118

119 We implemented preventive measures to improve the quality, continuity, and reliability of the
120 collected data. Each day, if by 7 pm, participants had not yet filled out the daily questionnaire,
121 they received a reminder notification through the PerMed application. Furthermore, we used a
122 dedicated dashboard to identify participants who continually neglected to complete the daily
123 questionnaires; these participants were contacted by the survey company and were encouraged to
124 better adhere to the study protocol.

125

126 **The smartwatch**

127 Participants were equipped with Garmin Vivosmart 4 smart fitness trackers. Among other
128 features, the smartwatch provides all-day heart rate and heart rate variability tracking capabilities
129 (24).

130

131 The optical wrist heart rate (HR) monitor of the smartwatch is designed to continuously monitor
132 a user's heart rate. The frequency at which heart rate is measured varies and may depend on the
133 level of activity of the user: when the user starts an activity, the optical HR monitor's
134 measurement frequency increases. Examining the data collected in our study, we identified an
135 HR sample roughly every 15 seconds.

136

137 Since heart rate variability (HRV) is not easily accessible through Garmin's application
138 programming interface (API), we use Garmin's stress level instead, which is calculated based on
139 HRV. Specifically, the device uses heart rate data to determine the interval between each
140 heartbeat. The variable length of time between each heartbeat is regulated by the body's
141 autonomic nervous system. Less variability between beats correlates with higher stress levels,
142 whereas an increase in variability indicates less stress (25). A similar relationship between HRV
143 and stress was also seen in (26,27).

144

145 While the Garmin smartwatch provides state-of-the-art wrist monitoring, it is not a medical-
146 grade device, and some readings may be inaccurate under certain circumstances, depending on
147 factors such as the fit of the device and the type and intensity of the activity undertaken by a
148 participant (28–30).

149

150 **Statistical analysis**

151 Questionnaire data were preprocessed by manually categorizing any self-reported symptom
152 entered as free text. In addition, if participants filled out the questionnaire more than once in one
153 day, the last entry from that day was used in the analysis. Smartwatch data were preprocessed as
154 follows. First, we computed the mean value of each hour of data. We then performed linear
155 interpolation to impute missing hourly means. Lastly, we smoothed the data by calculating the
156 five-hour moving average.

157

158 For each participant, we defined the 7-day period prior to vaccination as the baseline period. We
159 noted any pre-existing clinical symptoms from the last questionnaire completed during the
160 baseline period. Next, we calculated the percentage of participants who reported new (that is, not
161 pre-existing) local or systemic reactions in the 48 hours after vaccination. For each reaction, we
162 used a beta distribution to determine a 90% confidence interval.

163

164 We also calculated the mean difference in well-being indicators between the post-vaccination
165 period and the baseline period. Specifically, for each indicator, for each of the three days post-
166 vaccination and for each participant, we calculated the difference between that indicator's value
167 and its corresponding value in the baseline period. Then, we calculated the mean value over all
168 participants and the associated 90% confidence interval.

169

170 To compare the changes in smartwatch physiological indicators over the seven days (168 hours)
171 post vaccination with those of the baseline period, we performed the following steps. First, for
172 each participant and each hour during the seven days post vaccination, we calculated the

173 difference between that hour's indicator value and that of the corresponding hour in the baseline
174 period (keeping the same day of the week and same hour during the day). Then, we aggregated
175 each hour's differences over all participants to calculate a mean difference and associated 90%
176 confidence interval, which is analogous to a one-sided t-test with significance level 0.05.

177
178 We repeated the above analyses for the third dose stratified by age groups (≥ 50 vs. < 50), gender
179 (males vs. females) and the existence of an underlying medical condition (present vs. not
180 present) from the list specified in Table 1.

181
182 **Ethical Approval**

183 Before participating in the study, all subjects were advised, both orally and in writing, as to the
184 nature of the study and gave written informed consent. The study was approved by MHS'
185 Helsinki institutional review board, protocol number 0122-20-MHS.

186
187 **Results**

188 Of the 1,503 participants who received at least one dose of the BNT162b2 vaccine after joining
189 the study, 796 (52.96%) were women, and 707 (47.04%) were men. Their age ranged between 19
190 and 88 years, with a median age of 53 (Table 1). 1,173 (78.04%) participants had a body mass
191 index below 30, and 404 (26.88%) had at least one specific underlying medical condition (Table
192 1). The distributions of age and gender and the existence of underlying medical conditions were
193 relatively invariable across the recipients of the first, second and third dose (Table 1).

194
Table 1. Characteristics of the participants

Characteristic	All Participants (N=1,503)	First Dose (N=223)	Second Dose (N=351)	Third Dose (N=1,231)
Gender				
Male	47.04% (707)	45.29% (101)	45.58% (160)	47.93% (590)
Female	52.96% (796)	54.71% (122)	54.42% (191)	52.07% (641)
Age group				
18-29 yr	12.51% (188)	6.28% (14)	11.11% (39)	11.86% (146)
30-39 yr	15.9% (239)	4.93% (11)	15.1% (53)	15.11% (186)
40-49 yr	10.98% (165)	6.73% (15)	11.97% (42)	10.24% (126)
50-59 yr	26.95% (405)	28.7% (64)	24.79% (87)	28.92% (356)
60-69 yr	23.62% (355)	31.39% (70)	21.37% (75)	24.7% (304)
≥ 70 yr	10.05% (151)	21.97% (49)	15.67% (55)	9.18% (113)
Body-mass index*				
< 30.0	78.04% (1,173)	78.48% (175)	79.77% (280)	77.42% (953)
≥ 30.0	20.56% (309)	18.39% (41)	17.09% (60)	21.61% (266)
Unspecified	1.4% (21)	3.14% (7)	3.13% (11)	0.97% (12)
Underlying Medical Condition				
Hypertension	15.04% (226)	20.63% (46)	15.95% (56)	15.52% (191)
Diabetes	9.12% (137)	13% (29)	7.98% (28)	8.94% (110)
Heart disease	5.06% (76)	7.17% (16)	4.56% (16)	5.36% (66)
Chronic lung disease	5.06% (76)	4.93% (11)	3.7% (13)	5.28% (65)
Immune suppression	0.86% (13)	1.35% (3)	0.85% (3)	0.97% (12)
Cancer	0.6% (9)	0.45% (1)	0.57% (2)	0.65% (8)
Renal failure	0.53% (8)	1.79% (4)	1.42% (5)	0.49% (6)
None of the above	71.99% (1,082)	64.57% (144)	72.08% (253)	71.57% (881)


Unspecified 1.13% (17) 1.35% (3) 2.85% (10) 0.57% (7)

* The body-mass index is the weight in kilograms divided by the square of the height in meters

195

196 Our examination of the self-reported local and systemic reactions revealed that the reactions
 197 reported following the third vaccine dose are very similar to those reported following the second
 198 dose, and considerably greater than those observed following the first dose (Figure 1).
 199 Specifically, 65.4% (9 % CI: 62.8-67.8% of the participants did not report any new symptoms
 200 after receiving the third dose, compared to 87.7% (9 % CI: 83.2-91.0% and 66.2% (9 % CI:
 201 61.7-70.3% after the first and second doses, respectively. Moreover, the most frequently
 202 reported types of reactions—fatigue, headache, muscle pain, fever, and chills—were similar after
 203 the second and third doses. These reactions faded in nearly all participants within three days
 204 (Figure S10 in the Supplemental Material). Notably, these trends are consistent with those
 205 reported in the first and second dose BNT162b2 mRNA vaccine clinical trial (23).


206



207

208 **Figure 1. Local and systemic reactions reported by participants through the mobile application.** The
209 bars represent the percentage of participants who reported a given symptom. Error bars represent 90%
210 confidence intervals.

211
212 For the self-reported well-being indicators (Fig. 2), we found that during the first two days after
213 the third vaccine dose, participants exhibited a significant reduction in mood level (Fig. 2A),
214 sport duration (Fig. 2C), sleep quality (Fig. 2D) and a notable increase in stress level (Fig. 2B)
215 compared to baseline levels. These changes faded away on the third day post vaccination. A
216 similar trend can be observed after the second vaccine dose, with the exception of reported stress
217 level that remains below the baseline level during the second and third days post-vaccination.




218
219 **Figure 2. Changes in subjective well-being indicators reported by participants through the mobile**
220 **application.** Mean difference compared to baseline levels for the well-being indicators of (A) Mood
221 level, (B) Stress level, (C) Sport duration, and (D) Sleep quality. Mood level, Stress level, and Sleep

222 quality were reported on a 1-5 Likert scale. Sport duration was measured in minutes. Error bars represent
223 90% confidence intervals. Horizontal dashed lines represent no change compared to baseline levels.

224
225 We observed similar trends when analyzing the objective continuous physiological
226 measurements collected by the smartwatch (Fig. 3). Specifically, we identified a considerable
227 rise in both the heart rate and the heart rate variability-based stress indicators in the first 48 hours
228 following the administration of the third dose. Measurements returned to their baseline levels
229 within 72 hours. The trends observed for the objective indicators were consistent with those of
230 the subjective indicators also in the following sense - similar changes following the second and
231 third doses, and greater changes following the second and third doses compared to the first dose.

232



233 **Figure 3. Changes in objective physiological indicators measured through the smartwatch.** Mean
234 difference in smartwatch-recorded (A-C) heart rate and in (D-F) heart rate variability-based stress
235 indicators following the first, second and third dose, compared to their baseline levels. Mean values are
236 depicted as solid lines; 90% confidence intervals are presented as shaded regions. The horizontal dashed
237 line represents no change compared to the baseline levels, and vertical lines represent 24-hour periods.
238

239
240 We also stratified our analyses of well-being and smartwatch physiological indicators after the
241 third vaccination by age group, gender, and existence of a prior underlying medical condition.
242 For all stratifications, trends were similar to those observed in the general population. Namely,
243 there were considerable changes in the two days after vaccine administration that faded almost
244 entirely after three days (Figures S1-S9 in the Supplemental Material). We also found that
245 participants 50 years of age or older exhibited milder reactions than those below 50 years of age
246 (Figures S1, S4 and S7 in the Supplemental Material); male participants exhibited milder
247 reactions than female participants (Figures S2 and S8 in the Supplemental Material); and
248 participants with an underlying medical condition experienced milder reactions compared to
249 those without an underlying medical condition (Figures S3, S6 and S9 in the Supplemental
250 Material).

251
252 **Discussion**
253 Our key findings suggest that local and systemic reactions reported following the third (booster)
254 vaccine dose administration are very similar to those reported following the second dose and
255 considerably greater than those observed following the first dose. Our analyses of both self-
256 reported well-being indicators and objective smartwatch physiological indicators underscore
257 these results. Furthermore, within three days from inoculation with the third dose, all measures
258 returned to their baseline levels in nearly all participants.

259
260 We identified differences in subpopulations based on gender, age and underlying medical
261 condition following administration of the third vaccine dose. It has been previously suggested

262 that reactions caused by the COVID-19 vaccine are a byproduct of a short burst of IFN-I
263 generation concomitant with induction of an effective immune response (31). IFN-I generation is
264 substantially stronger in females than in males and stronger in younger and healthier individuals
265 than in older and less healthy ones. We found that participants below the age of 65, females, and
266 those without an underlying medical condition experienced greater reactions both in self-
267 reported local and systemic reactions and well-being indicators as well as in objective
268 physiological measurements recorded by the smartwatch. Our results are also in line with a
269 previous study that found similar trends after the first and second doses (32).

270
271 Clinical trials have not yet capitalized on the comprehensive physiological measures generated
272 by wearables. Currently, the FDA and European Medicines Agency (EMA) evaluate the safety
273 and create guidelines for newly developed vaccines primarily based on subjective, self-reported
274 questionnaires (33,34). Much of the scientific literature discusses these self-reported side effects
275 of COVID-19 vaccines. However, integrating wearables into clinical trials, alongside self-
276 reported questionnaires, can provide more precise and rich data regarding the vaccines' effects
277 on physiological measures.

278
279 Our study has several limitations. First, the 1,503 individuals who comprise the base cohort of
280 our analyses may not be representative of the vaccinated population in Israel or globally.
281 Nevertheless, the changes observed in self-reported reactions and well-being indicators as well
282 as objective physiological indicators recorded by the smartwatches were statistically significant
283 and consistent with each other. Moreover, the reaction types, frequency and duration we
284 observed for the first and second dose were similar to those observed in the BNT162b2 mRNA

285 vaccine clinical trials (23). In addition, a clear pattern of returning to baseline levels was
286 observed within 72 hours post inoculation in all examined measures. Lastly, although the sample
287 size was limited, trends were consistent regardless of age group, gender, and the existence of
288 underlying medical conditions.

289
290 Second, we did not explicitly control for the effects of the observational trial setting (i.e.,
291 participating in a trial, wearing a smartwatch, potential concerns regarding the vaccine, etc.).
292 Any effects of the observational trial setting should, in principle, have similar impacts on our
293 analysis of each of the three vaccine doses. However, since we found no deviations in most
294 measurements from baseline levels in the subset of participants who received their first dose, we
295 believe the changes observed after the second and third doses arise from an actual reaction to the
296 vaccine.

297
298 Third, the smartwatches used to obtain physiological measurements are not medical-grade
299 devices. Nevertheless, recent studies show a considerably accurate heart rate measurement in
300 the previous versions of the smartwatch used in this study (28,29). Moreover, our analysis
301 focused on the change in measurements compared to their baseline values rather than on their
302 absolute values.

303
304 Finally, the only vaccine available in Israel is the BNT162b2 mRNA vaccine. Although our
305 findings may not directly generalize to other types of COVID-19 vaccines, we believe that
306 applying our analyses on other vaccines are likely to yield qualitatively similar findings, due to
307 the similarities observed between different COVID-19 vaccines (23,35,36).

308

309 Our study strengthens the evidence regarding the short-term safety of the booster BNT162b2
310 vaccine in several ways. First, reports of local and systemic reactions following the third dose
311 were very similar to those observed following the second dose, which was already shown in
312 clinical trials to be safe (23). Second, the considerable changes observed in all indicators during
313 the first two days after receiving the third vaccine, including self-reported local and systemic
314 reactions and well-being indicators as well as objective physiological indicators collected by the
315 smartwatch, returned to their baseline levels. Third, regardless of the observed differences
316 between subpopulations, our analyses indicate a clear pattern of return to baseline levels in all
317 considered subpopulations.

318

319 In conclusion, our study supports the short-term safety of the third BNT162b2 mRNA COVID-
320 19 (booster) vaccine dose and mitigates, in part, concerns regarding its short-term effects. The
321 medical and scientific communities could greatly benefit from the largely unbiased data
322 generated by digital health technologies such as the wearable data which we analyzed in this
323 study. Our findings could also be of interest to public health officials and other stakeholders, as it
324 is important that objective measures are given attention in the critical evaluation of clinical trials.

325 **References**

- 326 1. Kupferschmidt K, Wadman M. Delta variant triggers new phase in the pandemic. *Science*
327 (80-) [Internet]. 2021 Jun 25 [cited 2021 Aug 22];372(6549):1375–6. Available from:
328 <https://science.sciencemag.org/content/372/6549/1375>
- 329 2. Tracking SARS-CoV-2 variants [Internet]. [cited 2021 Aug 22]. Available from:
330 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants>
- 331 3. Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2
332 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine
333 breakthrough. *bioRxiv* [Internet]. 2021 Aug 6 [cited 2021 Aug 22];2021.05.08.443253.
334 Available from: <https://www.biorxiv.org/content/10.1101/2021.05.08.443253v5>
- 335 4. Delta Variant: What We Know About the Science | CDC [Internet]. [cited 2021 Aug 22].
336 Available from: <https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html>
- 337 5. Mahase E. Delta variant: What is happening with transmission, hospital admissions, and
338 restrictions? *BMJ* [Internet]. 2021 Jun 15 [cited 2021 Aug 22];373:n1513. Available from:
339 <https://www.bmj.com/content/373/bmj.n1513>
- 340 6. Weekly epidemiological update on COVID-19 - 17 August 2021 [Internet]. [cited 2021
341 Aug 22]. Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---17-august-2021>
- 342
- 343 7. Wadman M. Israel’s grim warning: Delta can overwhelm shots. *Science* (80-) [Internet].
344 2021 Aug 20 [cited 2021 Aug 22];373(6557):838–9. Available from:
345 <https://science.sciencemag.org/content/373/6557/838>

- 346 8. Munitz A, Yechezkel M, Dickstein Y, Yamin D, Gerlic M. BNT162b2 vaccination
347 effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations
348 in Israel. *Cell Reports Med* [Internet]. 2021 Apr [cited 2021 May 3];0(0):100264.
349 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S266637912100080X>
- 350 9. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
351 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
352 <https://doi.org/101056/NEJMoa2108891> [Internet]. 2021 Jul 21 [cited 2021 Aug
353 22];385(7):585–94. Available from:
354 <https://www.nejm.org/doi/full/10.1056/NEJMoa2108891>
- 355 10. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Impact
356 of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in
357 the UK.
- 358 11. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland:
359 demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* [Internet].
360 2021 Jun 26 [cited 2021 Aug 22];397(10293):2461–2. Available from:
361 <http://www.thelancet.com/article/S0140673621013581/fulltext>
- 362 12. Nasreen S, He Msc S, Mph HC, Brown Phd KA, Gubbay JB, Buchan SA, et al.
363 Effectiveness of COVID-19 vaccines against variants of concern, Canada on behalf of the
364 Canadian Immunization Research Network (CIRN) Provincial Collaborative Network
365 (PCN) Investigators. [cited 2021 Aug 22]; Available from:
366 <https://doi.org/10.1101/2021.06.28.21259420>
- 367 13. COVID-19 Datasets- Government Data [Internet]. [cited 2020 May 30]. Available from:

- 368 <https://data.gov.il/dataset/covid-19>
- 369 14. The Ministry of Health Director General Has Approved the Recommendation to
370 Administer a Third Vaccine Dose to 50-Year-Olds and Older and to Other Populations |
371 Ministry of Health [Internet]. [cited 2021 Aug 22]. Available from:
372 <https://www.gov.il/en/departments/news/13082021-01>
- 373 15. The Vaccination Advisory Committee Presented Data and Recommended the
374 Administration of a Third Dose to Older Adults | Ministry of Health [Internet]. [cited 2021
375 Aug 22]. Available from: <https://www.gov.il/en/departments/news/29072021-04>
- 376 16. Statement by PM Bennett on Third Dose of the COVID Vaccine to Israeli Citizens over
377 the Age of 60 | Prime Minister's Office [Internet]. [cited 2021 Aug 22]. Available from:
378 https://www.gov.il/en/Departments/news/event_press290721
- 379 17. The Vaccination Policy and the New Green Pass that will Take Effect Soon | Ministry of
380 Health [Internet]. [cited 2021 Sep 15]. Available from:
381 <https://www.gov.il/en/departments/news/29082021-01>
- 382 18. Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster
383 Shots | CDC Online Newsroom | CDC [Internet]. [cited 2021 Aug 22]. Available from:
384 <https://www.cdc.gov/media/releases/2021/s0818-covid-19-booster-shots.html>
- 385 19. COVID-19 Vaccines for Moderately to Severely Immunocompromised People | CDC
386 [Internet]. [cited 2021 Aug 22]. Available from: [https://www.cdc.gov/coronavirus/2019-
387 ncov/vaccines/recommendations/immuno.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html)
- 388 20. Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster

- 389 Shots | FDA [Internet]. [cited 2021 Aug 23]. Available from: [https://www.fda.gov/news-](https://www.fda.gov/news-events/press-announcements/joint-statement-hhs-public-health-and-medical-experts-covid-19-booster-shots)
390 [events/press-announcements/joint-statement-hhs-public-health-and-medical-experts-](https://www.fda.gov/news-events/press-announcements/joint-statement-hhs-public-health-and-medical-experts-covid-19-booster-shots)
391 [covid-19-booster-shots](https://www.fda.gov/news-events/press-announcements/joint-statement-hhs-public-health-and-medical-experts-covid-19-booster-shots)
- 392 21. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Bello A Del. Three Doses of an
393 mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.
394 <https://doi.org/10.1056/NEJMc2108861> [Internet]. 2021 Jun 23 [cited 2021 Aug
395 23];385(7):661–2. Available from: <https://www.nejm.org/doi/10.1056/NEJMc2108861>
- 396 22. Oved S, Mofaz M, Lan A, Einat H, Kronfeld-Schor N, Yamin D, et al. Differential effects
397 of COVID-19 lockdowns on well-being: interaction between age, gender and chronotype
398 [Internet]. 2021 Jan [cited 2021 Mar 31]. Available from:
399 <https://www.researchsquare.com>
- 400 23. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
401 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* [Internet]. 2020 Dec
402 31 [cited 2021 Mar 31];383(27):2603–15. Available from:
403 <http://www.nejm.org/doi/10.1056/NEJMoa2034577>
- 404 24. VÍVOSMART ® 4 Owner’s Manual. 2018 [cited 2021 Aug 23]; Available from:
405 www.garmin.com
- 406 25. What Is the Stress Level Feature on My Garmin Watch? | Garmin Support [Internet].
407 [cited 2021 Aug 24]. Available from: [https://support.garmin.com/en-](https://support.garmin.com/en-US/?faq=WT9BmhjacO4ZpxbCc0EKn9)
408 [US/?faq=WT9BmhjacO4ZpxbCc0EKn9](https://support.garmin.com/en-US/?faq=WT9BmhjacO4ZpxbCc0EKn9)
- 409 26. Kim H-G, Cheon E-J, Bai D-S, Lee YH, Koo B-H. Stress and Heart Rate Variability: A
410 Meta-Analysis and Review of the Literature. *Psychiatry Investig* [Internet]. 2018 Mar 1

- 411 [cited 2021 Aug 24];15(3):235. Available from: </pmc/articles/PMC5900369/>
- 412 27. Pereira T, Almeida PR, Cunha JPS, Aguiar A. Heart rate variability metrics for fine-
413 grained stress level assessment. *Comput Methods Programs Biomed.* 2017 Sep 1;148:71–
414 80.
- 415 28. RK R, R P, DP Z, B S, J EY, E D, et al. Accuracy of Wrist-Worn Activity Monitors
416 During Common Daily Physical Activities and Types of Structured Exercise: Evaluation
417 Study. *JMIR mHealth uHealth* [Internet]. 2018 Dec 1 [cited 2021 Aug 23];6(12).
418 Available from: <https://pubmed.ncbi.nlm.nih.gov/30530451/>
- 419 29. Bent B, Goldstein BA, Kibbe WA, Dunn JP. Investigating sources of inaccuracy in
420 wearable optical heart rate sensors. *npj Digit Med* 2020 31 [Internet]. 2020 Feb 10 [cited
421 2021 Aug 23];3(1):1–9. Available from: [https://www.nature.com/articles/s41746-020-](https://www.nature.com/articles/s41746-020-0226-6)
422 0226-6
- 423 30. Accuracy | Garmin [Internet]. [cited 2021 Aug 22]. Available from:
424 <https://www.garmin.com/en-US/legal/atdisclaimer/>
- 425 31. Bunders MJ, Altfeld M. Implications of Sex Differences in Immunity for SARS-CoV-2
426 Pathogenesis and Design of Therapeutic Interventions. *Immunity.* 2020 Sep 15;53(3):487–
427 95.
- 428 32. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects
429 and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app
430 in the UK: a prospective observational study. *Lancet Infect Dis* [Internet]. 2021 Jul 1
431 [cited 2021 Aug 24];21(7):939–49. Available from:
432 <http://www.thelancet.com/article/S1473309921002243/fulltext>

- 433 33. Development and Licensure of Vaccines to Prevent COVID-19 | FDA [Internet]. [cited
434 2021 Mar 31]. Available from: [https://www.fda.gov/regulatory-information/search-fda-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19)
435 [guidance-documents/development-and-licensure-vaccines-prevent-covid-19](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19)
- 436 34. Clinical trials in human medicines | European Medicines Agency [Internet]. [cited 2021
437 Aug 23]. Available from: [https://www.ema.europa.eu/en/human-regulatory/research-](https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials-human-medicines)
438 [development/clinical-trials-human-medicines](https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials-human-medicines)
- 439 35. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety
440 of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* [Internet]. 2021 Feb 4 [cited
441 2021 Mar 31];384(5):403–16. Available from:
442 <http://www.nejm.org/doi/10.1056/NEJMoa2035389>
- 443 36. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety
444 and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an
445 interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
446 *Lancet* [Internet]. 2021 Jan 9 [cited 2021 Mar 31];397(10269):99–111. Available from:
447 <https://doi.org/10.1016/>
448

449 **Financial Support**

450 This research was supported by the European Research Council (ERC) project #949850 and the
451 Israel Science Foundation (ISF), grant No. 3409/19, within the Israel Precision Medicine
452 Partnership program. MLB and GG received support from the Koret foundation grant for
453 Smart Cities and Digital Living 2030.

454

455 **Data availability**

456 Researchers interested in obtaining an aggregated version of the data sufficient to reproduce the
457 results reported in this paper should contact the corresponding author.

458

459 **Authors' contributions**

460 Conception and design: DY, ES. Collection and assembly of data: MM, TP, SG, ES. Analysis
461 and interpretation of the data: MM, GG, MLB, DY, ES. Statistical expertise: MM, DY, ES.
462 Drafting the article: MM, MY, DY, ES. Critical revision of the article for important intellectual
463 content: DY, ES. Final approval of the article: All authors. Obtaining funding: DY, ES.

464

465 **Disclosures**

466 All authors have disclosed no conflicts of interest.

467

468 **Reproducible Research Statement**

469 Further details are available from Dr. Erez Shmueli (e-mail, shmueli@tau.ac.il).

470 Statistical code will be available after acceptance.

484 **Appendix A: Self-reported questionnaires**

485

486 *Enrollment questionnaire*

487 All participants will fill a one-time enrollment questionnaire that includes demographic questions
488 and questions about the participant's health condition in general. Specifically, the questionnaire
489 will include the following: age, gender, height, weight and underlying medical conditions (Listed
490 in Table 1, main text). Other questions such as name, address, phone number and email will be
491 recorded and used by the survey company to contact the participants. The answers will be filled-
492 in directly by the survey company to the study's secured dashboard.

493

494 *Vaccination questionnaire*

495 The vaccination questionnaire we will use includes the following question:

- 496 ○ COVID-19 vaccination – date, time and dose number.

497

498 *Daily questionnaire*

499 All participants will complete the daily self-reported questionnaire in a dedicated application (the
500 PerMed mobile application). The daily questionnaire we will use includes the following
501 questions:

- 502 ○ How is your mood today? • Awful (1) • Bad (2) • OK (3) • Good (4) • Excellent (5)
- 503 ○ How would you describe the level of your stress during the last day? • Very Low (1) •
504 Low (2) • Medium (3) • High (4) • Very high (5)
- 505 ○ How would you define your last night sleep quality? • Awful (1) • Bad (2) • OK (3) •
506 Good (4) • Excellent (5)
- 507 ○ Try to remember how many minutes of sports activity you performed on the last day?


- 508 ○ Have you experienced one or more of the following symptoms in the last 24 hours? • My
509 general feeling is good, and I have no symptoms • Heat measured above 37.5 • Cough •
510 Sore throat • Runny nose • Headache • Shortness of breath • Muscle aches • Weakness /
511 fatigue • Diarrhea • Nausea / vomiting • Chills • Confusion • Loss of sense of taste / smell
512 • Other symptom.
- 513

514 **Appendix B: Additional Results**

515 **Reported local and systemic reactions – stratification by age group**

516 We observe that the local and systemic reactions reported following the third dose were milder

517 for participants older than years compared to those younger than years (Figure S1).



518

519 **Figure. S1. Local and systemic reactions reported by participants through the mobile**


520 **application stratified by age group.** The bars represent the percentage of participants who

521 reported a given symptom. Error bars represent 90% confidence intervals.

522 **Reported local and systemic reactions – stratification by gender**

523 We observe that the local and systemic reactions reported following the third dose were milder in

524 males compared to females (Figure S2).



525

526 **Figure. S2. Local and systemic reactions reported by participants through the mobile**


527 **application stratified by gender.** The bars represent the percentage of participants who reported

528 a given symptom. Error bars represent 90% confidence intervals.

529 **Reported local and systemic reactions – stratification by underlying medical condition**

530 We observe that the local and systemic reactions reported following the third dose were milder

531 for participants with underlying medical conditions compared to those without (Figure S3).



532

533 **Figure. S3. Local and systemic reactions reported by participants through the mobile**

534 **application stratified by underlying medical condition.** The bars represent the percentage of


535 participants who reported a given symptom. Error bars represent 90% confidence intervals.

536 **Changes in reported well-being indicators – stratification by age group**

537 Changes in well-being observed during the first two days after the third vaccine dose were found

538 to be higher for participants younger than 50 years compared to those older than 50 years, with

539 the exception of reported stress level (Figure S4).



540

541 **Figure S4. Changes in well-being indicators reported by participants through the mobile**

542 **application stratified by age group.** (A) mood level, measured on a 1-to-5 Likert scale. (B)

543 Stress level, measured on a 1-to-5 Likert scale. (C) Sport duration, measured in minutes. (D)

544 Sleep quality, measured on a 1-to-5 Likert scale. Changes in well-being indicators were


545 calculated by subtracting the baseline values from the daily values. Error bars represent 90%

546 confidence intervals. Horizontal dashed lines represent no change compared to baseline levels.

547 **Changes in reported well-being indicators – stratification by gender**

548 Changes in well-being observed during the first two days after the third vaccine dose were found

549 to be similar for males and females (Figure S5).



550

551 **Figure S5. Changes in well-being indicators reported by participants through the mobile**

552 **application stratified by gender.** (A) mood level, measured on a 1-to-5 Likert scale. (B) Stress


553 level, measured on a 1-to-5 Likert scale. (C) Sport duration, measured in minutes. (D) Sleep

554 quality, measured on a 1-to-5 Likert scale. Changes in well-being indicators were calculated by

555 subtracting the baseline values from the daily values. Error bars represent 90% confidence

556 intervals. Horizontal dashed lines represent no change compared to baseline levels.

557 **Changes in reported well-being indicators – stratification by underlying medical condition**
558 Changes in well-being observed during the first two days after the third vaccine dose were found
559 to be higher for participants without underlying medical conditions compared to those with
560 underlying medical condition, with the exception of reported stress level (Figure S6).




561

562 **Figure S6. Changes in well-being indicators reported by participants through the mobile**
563 **application stratified by underlying medical conditions.** (A) mood level, measured on a 1-to-5
564 Likert scale. (B) Stress level, measured on a 1-to-5 Likert scale. (C) Sport duration, measured in
565 minutes. (D) Sleep quality, measured on a 1-to-5 Likert scale. Changes in well-being indicators
566 were calculated by subtracting the baseline values from the daily values. Error bars represent 90%
567 confidence intervals. Horizontal dashed lines represent no change compared to baseline levels.

568 **Changes in physiological indicators – stratification by age group**

569 Changes in physiological indicators after the third vaccine dose stratified by age group were
570 consistent with those observed in the general population (considerable changes during the first
571 two days after vaccine administration that faded nearly entirely after three days). These changes
572 were found to be higher for participants younger than 50 years compared to those older than 50



573 years (Figure S7).

574 **Figure S7. Changes in physiological indicators measured through the smartwatch stratified**

575 **by age groups.** Mean difference in heart rate and heart rate variability-based stress indicators

576 following the third dose, recorded by a smartwatch, compared to their baseline levels: (A and B)


577 heart rate, (C and D) heart rate variability-based stress. Mean values are depicted as solid lines;

578 90% confidence intervals are presented as shaded regions. The horizontal dashed line represents

579 no change compared to the baseline levels, and vertical lines represent 24-hour periods.

580 **Changes in physiological indicators – stratification by gender**

581 Changes in physiological indicators after the third vaccine dose stratified by gender were
582 consistent with those observed in the general population (considerable changes during the first
583 two days after vaccine administration that faded nearly entirely after three days). These changes



584 were found to be higher for females compared to males (Figure S8).

585 **Figure S8. Changes in physiological indicators measured through the smartwatch stratified**

586 **by gender.** Mean difference in heart rate and heart rate variability-based stress indicators


587 following the third dose, recorded by a smartwatch, compared to their baseline levels: **(A and B)**

588 heart rate, **(C and D)** heart rate variability-based stress. Mean values are depicted as solid lines;

589 90% confidence intervals are presented as shaded regions. The horizontal dashed line represents


590 no change compared to the baseline levels, and vertical lines represent 24-hour periods.

591 **Changes in physiological indicators – stratification by underlying medical condition**
592 Changes in physiological indicators after the third vaccine dose stratified by underlying medical
593 condition were consistent with those observed in the general population (considerable changes
594 during the first two days after vaccine administration that faded nearly entirely after three days).
595 These changes were found to be higher for participants without underlying medical conditions
596 compared to those with underlying medical condition (Figure S9).



597 **Figure S9. Changes in physiological indicators measured through the smartwatch stratified**
598 **by underlying medical conditions.** Mean difference in heart rate and heart rate variability-based
599 stress indicators following the third dose, recorded by a smartwatch, compared to their baseline
600 levels: (A and B) heart rate, (C and D) heart rate variability-based stress. Mean values are
601 depicted as solid lines; 90% confidence intervals are presented as shaded regions. The horizontal
602 dashed line represents no change compared to the baseline levels, and vertical lines represent 24-
603 hour periods.

604 **14 days analysis for self-reported local and systemic reactions after the third dose**
605 We observe a sharp decline in reported local and systemic reactions following three days after the
606 third vaccination dose, and nearly a complete halt within 14 days post-vaccination (Figure S10).
607 Fatigue and headache were the most frequent reactions reported and lasted longer than the other
608 reported reactions.



609
610 **Figure S10. Most frequent local and systemic reactions reported by participants through the**
611 **mobile application after the third dose. (A) fatigue, (B) headache, (C) muscle pain, (D) fever,**
612 **and (E) chills. Error bars represent 90% confidence intervals.**

613 **Number of participants receiving each vaccine dose**

614 1,503 participants reported receipt of at least one of the three BNT162b2 mRNA COVID-19
615 vaccine shots after joining the study. Specifically, out of these 1,503 participants serving as the
616 base cohort for our analyses, 223 received during the study period their first dose, 351 their
617 second dose, and 1,231 their third dose (Table S1).

Table S1. Number of participants receiving each vaccine dose

Dose administered	Number of participants (n)
First dose only	26
Second dose only	129
Third dose only	1,122
All three doses	76
First and second doses	117
First and third doses	4
Second and third doses	29

618

619